Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:VLON Vallon Pharmaceuticals (VLON) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrends About Vallon Pharmaceuticals Stock (NASDAQ:VLON) 30 days 90 days 365 days Advanced Chart Ad Genesis Gold GroupBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Get Vallon Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.63▼$0.7050-Day Range$0.27▼$2.8752-Week Range$0.21▼$12.92Volume311,641 shsAverage Volume5.78 million shsMarket Capitalization$9.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewVallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.Read More… Buffett Dumps $982 Million in BofA Stock—What Does He Know? (Ad)Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Receive VLON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vallon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address VLON Stock News HeadlinesQuestcor Pharmaceuticals,July 21, 2023 | forbes.comVallon Pharmaceuticals' shareholders approve reverse merger with California companyApril 20, 2023 | bizjournals.comWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.November 21, 2024 | DTI (Ad)Vallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock SplitApril 20, 2023 | finance.yahoo.comVallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023April 12, 2023 | finance.yahoo.comLab Notes: CHOP gets $10M research gift; Vallon seeks greater shareholder support for mergerApril 7, 2023 | bizjournals.comVallon Pharmaceuticals Provides an Update on Proxy Voting for the Proposed Merger with GRI Bio and Urges Stockholders of Record as of March 6, 2023 to Vote by April 11, 2023, at 11:59 PM ETApril 4, 2023 | finance.yahoo.comVallon Pharmaceuticals Inc.: Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial ResultsFebruary 24, 2023 | finanznachrichten.deSee More Headlines VLON Stock Analysis - Frequently Asked Questions When did Vallon Pharmaceuticals' stock split? Shares of Vallon Pharmaceuticals reverse split before market open on Monday, April 24th 2023. The 1-30 reverse split was announced on Monday, April 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Vallon Pharmaceuticals IPO? Vallon Pharmaceuticals (VLON) raised $15 million in an IPO on Wednesday, February 10th 2021. The company issued 1,700,000 shares at a price of $8.00-$10.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO. What other stocks do shareholders of Vallon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vallon Pharmaceuticals investors own include Meta Platforms (META), Alkaline Water (WTER), SoFi Technologies (SOFI), Exro Technologies (EXROF), AMC Entertainment (AMC), Alpha Lithium (APHLF) and Avino Silver & Gold Mines (ASM). Company Calendar Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VLON CUSIPN/A CIK1824293 Webwww.vallon-pharma.com Phone267-607-8255FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,020,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-230.48% Return on Assets-124.89% Debt Debt-to-Equity RatioN/A Current Ratio2.29 Quick Ratio2.29 Sales & Book Value Annual Sales$100,000.00 Price / Sales86.15 Cash FlowN/A Price / Cash FlowN/A Book Value$0.18 per share Price / Book3.55Miscellaneous Outstanding Shares13,482,000Free Float8,453,000Market Cap$8.61 million OptionableNot Optionable Beta-1.14 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:VLON) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vallon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vallon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.